Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 78

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
(4,992,832)(37)%Loss from operations(8,408,918)(13,381,939)4,973,021 (37)%Other income (expense)Sale of royalty and milestone rights, net— 20,379,376 (20,379,376)(100)%Other income (expense), net14,128 (842,137)856,265 (102)%Net income (loss)$(8,394,790)$6,155,300 $(14,550,090)(236)%Other comprehensive income (loss):Foreign currency translation adjustments25,983 (24,664)50,647 (205)%Comprehensive income (loss)$(8,368,807)$6,130,636 $(14,499,443)(237)%

Revenues

Revenues for the six months ended June 30, 2025 and June 30, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information. An adjustment for lower actual royalty revenue than we previously estimated for the three months ended March 31, 2025 resulted in lower non-cash royalty revenue reported for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. See “—Financial Overview—Revenue,” above.

General and administrative expenses

The decrease of approximately $0.4 million in general and administrative expenses for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024 was primarily attributable to decreases in stock-based compensation expense of approximately $0.4 million and personnel costs of approximately $0.3 million. Such decreases were partially offset by increased professional services expense of approximately $0.2 million.

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

39

Six Months EndedJune 30,Change20252024$%Direct program costs:Ovaprene (1)$2,812,101 $5,163,358 $(2,351,257)(46)%Sildenafil Cream, 3.6%261,270 1,166,510 (905